Pregenerate
Vienna
About Pregenerate
At Pregenerate, we use scaleable organ-on-a-chip models to replace animal testing in pharmaceutical research for arthritis treatments. This enables pharmaceutical companies to save billions of dollars and improve the success rates of their drugs to market, in part because we can use human cells in our model.Ultimately, this same technology will allow us to stratify patients into targeted treatment subgroups, and even to tell each clinical patient what the best treatment is for his or her specific arthritis needs directly.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $130.0K
- Funding stage: Seed
- Last round: Convertible Note (Jun 2022)
- Website: pregenerate.net
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Medical Device, Precision Medicine
Social Profiles
Canonical: https://fsome.com/organization/pregenerate-191222 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.